Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Günter Niegisch

Showing results (1-10 of 114) with videos related to

Pageof 12
Sort By:
Aktuelle Urologie|June 21, 2017
[Urothelial cancer: update on systemic treatment options]Günter Niegisch
Translational Andrology and Urology|August 9, 2019
Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?Günter Niegisch
British Journal of Cancer|December 21, 2019
Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?Günter Niegisch
Translational Andrology and Urology|January 29, 2019
Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?Günter Niegisch
Aktuelle Urologie|March 28, 2022
Günter Niegisch
Methods in Molecular Biology (Clifton, N.J.)|July 6, 2023
Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial CarcinomaGünter Niegisch
The New England Journal of Medicine|March 6, 2024
Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial CancerGünter Niegisch
Urologie (Heidelberg, Germany)|October 7, 2024
[Current developments in urothelial carcinoma]Günter Niegisch, Mario Kramer
Current Opinion in Urology|July 9, 2011
Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?Günter Niegisch, Peter Albers
Urologic Oncology|August 5, 2017
Targeting mTOR in urothelial cancer-Beating a dead horse or ready for prime time?Günter Niegisch, Peter Albers
Pageof 12

Showing results (1-10 of 114) with videos related to

Sort By:
Pageof 12
Aktuelle Urologie|June 21, 2017
[Urothelial cancer: update on systemic treatment options]Günter Niegisch
Translational Andrology and Urology|August 9, 2019
Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?Günter Niegisch
British Journal of Cancer|December 21, 2019
Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?Günter Niegisch
Translational Andrology and Urology|January 29, 2019
Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?Günter Niegisch
Aktuelle Urologie|March 28, 2022
Günter Niegisch
Methods in Molecular Biology (Clifton, N.J.)|July 6, 2023
Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial CarcinomaGünter Niegisch
The New England Journal of Medicine|March 6, 2024
Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial CancerGünter Niegisch
Urologie (Heidelberg, Germany)|October 7, 2024
[Current developments in urothelial carcinoma]Günter Niegisch, Mario Kramer
Current Opinion in Urology|July 9, 2011
Which patients benefit the most from neoadjuvant chemotherapy in advanced bladder cancer?Günter Niegisch, Peter Albers
Urologic Oncology|August 5, 2017
Targeting mTOR in urothelial cancer-Beating a dead horse or ready for prime time?Günter Niegisch, Peter Albers
Pageof 12